Variable | Median (IQR) or % (n, of 518) | Â |
---|---|---|
Age at diagnosis | 60 (50–68) |  |
Percent female | 46% (238) | Â |
Race | Â | |
 White | 66% (340) |  |
 East Asian | 14% (74) |  |
 African American | 8.7% (45) |  |
 Southeast Asian | 3.7% (19) |  |
 Asian NOS | 3.7% (19) |  |
 Other (includes American Indian, Pacific Islander) | 4.1% (21) |  |
Percent Hispanic | 9.1% (47) | Â |
Survival time since diagnosis (months) | 28 (11–53) |  |
Primary diagnosis | Â | |
 Lung | 26% (137) |  |
 Breast | 19% (97) |  |
 Prostate | 9.7% (50) |  |
 Renal cell | 5.8% (30) |  |
 Colorectal | 5.8% (30) |  |
 Hepatocellular | 3.8% (20) |  |
 Head and Neck | 3.5% (18) |  |
 Skin | 3.3% (17) |  |
 Othera | 23% (119) |  |
Metastatic at diagnosis | 49% (254) | Â |
Site of metastases | Â | |
 Brain | 47% (244) |  |
 Lung | 55% (284) |  |
 Liver | 40% (208) |  |
Bone only | 17% (90) | Â |
BMI last course | 24(21–27) |  |
KPS last consult | 60 (50–80) |  |
 KPS > 70 | 45% (231/511) |  |
Hospitalization within 3 months of RT consult | 58% (289/500) |  |
TEACHH scoreb | Â | Median survival, months (IQR) |
 0–1 (Group A) | 6.2% (32/450) | 6 (2.8–11) |
 2–4 (Group B) | 68% (352/450) | 2.2 (1.0–5.0) |
 5–6 (Group C) | 13% (66/450) | 1.3 (0.5–2.3) |
CHOW groupb | ||
 I | 18% (92/510) | 4.7 (2–11) |
 II | 44% (227/510) | 2.5 (1.0–5.6) |
 III | 37% (191/510) | 1.6 (0.7–2.7) |
Hospice involved | Â | |
 Yes | 47% (245) |  |
 No | 28% (147) |  |
 Unknown | 24% (126) |  |
Place of death | Â | |
 Inpatient, acute care | 23% (120) |  |
 Home | 29% (151) |  |
 Inpatient hospice, non-acute care | 10% (52) |  |
 SNF (not hospice) | 1.5% (8) |  |
 Unknown | 36% (187) |  |